Welcome to our dedicated page for NASCENT BIOTECH news (Ticker: NBIO), a resource for investors and traders seeking the latest updates and insights on NASCENT BIOTECH stock.
Nascent Biotech, Inc. (OTCMKTS:NBIO) is a clinical-stage biotechnology company formed in 2014. The company focuses on developing pritumumab, a human monoclonal antibody designed to target brain and pancreatic cancers. With a team of leading scientists specializing in monoclonal antibodies and cytokine treatments, Nascent aims to modulate the human body's immune response through immunotherapy. The combination of monoclonal antibodies and cytokines enhances therapeutic effectiveness against various diseases. Nascent Biotech is pioneering innovative cancer treatments that prioritize patient outcomes and shareholder value.
Nascent Biotech (OTCQB:NBIO) has received a notification from OTC Markets Group due to failing to file its Q3 2024 Form 10-Q on time. As a consequence, the company's stock has been moved from regular OTC Markets platforms to the 'Expert Market.' The company is actively working with auditors and legal advisors to complete the delayed filing and return to compliance with OTC Markets' listing requirements.
CEO Sean Carrick stated the company is committed to resolving the situation promptly and maintaining transparency. Once the filing requirements are met, NBIO expects its stock to resume normal quotation on OTC Markets' trading platforms.
Nascent Biotech (OTCQB:NBIO) presented at the Emerging Growth Conference on July 18, 2024, highlighting its progress in developing Pritumumab (PTB), a monoclonal antibody targeting various cancer types. CEO Sean Carrick discussed:
1. PTB's successful Phase I results and safety profile
2. Plans for Phase II trials focusing on brain cancer, with potential expansion to pancreatic and colorectal cancers
3. Timeline for manufacturing completion by year-end and Phase II trials starting in Q1 2025
4. The company's de-risked investment profile and need for funding to advance clinical trials
Nascent aims to begin expanded access trials for digestive cancers in Q2 2025, leveraging PTB's potential across multiple cancer types.
FAQ
What is the current stock price of NASCENT BIOTECH (NBIO)?
What is the market cap of NASCENT BIOTECH (NBIO)?
When was Nascent Biotech, Inc. established?
What is the focus of Nascent Biotech, Inc.'s research and development?
What is Nascent Biotech, Inc.'s clinical premise for treating diseases?
How does Nascent Biotech, Inc. distinguish itself in the biotechnology sector?
What are Nascent Biotech, Inc.'s primary areas of focus for disease treatment?
